Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Total Liabilities (2016 - 2025)

Sutro Biopharma's Total Liabilities history spans 10 years, with the latest figure at $296.9 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 12.83% year-over-year to $296.9 million; the TTM value through Sep 2025 reached $296.9 million, down 12.83%, while the annual FY2024 figure was $342.6 million, 6.7% up from the prior year.
  • Total Liabilities for Q3 2025 was $296.9 million at Sutro Biopharma, up from $294.5 million in the prior quarter.
  • Across five years, Total Liabilities topped out at $347.2 million in Q1 2025 and bottomed at $51.2 million in Q1 2021.
  • The 5-year median for Total Liabilities is $294.5 million (2025), against an average of $225.7 million.
  • The largest annual shift saw Total Liabilities fell 28.69% in 2021 before it surged 237.67% in 2022.
  • A 5-year view of Total Liabilities shows it stood at $88.8 million in 2021, then surged by 113.74% to $189.9 million in 2022, then skyrocketed by 69.09% to $321.1 million in 2023, then increased by 6.7% to $342.6 million in 2024, then fell by 13.33% to $296.9 million in 2025.
  • Per Business Quant, the three most recent readings for STRO's Total Liabilities are $296.9 million (Q3 2025), $294.5 million (Q2 2025), and $347.2 million (Q1 2025).